Pharsight

Delcath Systems Inc patents expiration

1. Hepzato patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11241522 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(9 years from now)

US10369264 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(9 years from now)

US10098997 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(9 years from now)

US11633528 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Nov, 2032

(9 years from now)

US11083831 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Dec, 2032

(9 years from now)

US10195334 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Jan, 2033

(9 years from now)

US9314561 DELCATH SYSTEMS INC Filter and frame apparatus and method of use
Feb, 2034

(10 years from now)

US9707331 DELCATH SYSTEMS INC Apparatus for removing chemotherapy compounds from blood
Sep, 2034

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Aug 14, 2030

Drugs and Companies using MELPHALAN HYDROCHLORIDE ingredient

Market Authorisation Date: 14 August, 2023

Treatment: A percutaneous hepatic perfusion procedure for treating a patient with uveal melanoma with unresectable hepatic metastases

Dosage: POWDER;INTRA-ARTERIAL

More Information on Dosage

HEPZATO family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic